HC Wainwright & Co. Downgrades Fulcrum Therapeutics to Neutral, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 93.0%

Neg 93% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Neutral and lowers the price target from $25 to $3.